Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation and Intervention for the Effects of Osteogenesis Imperfecta
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), November 2008
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001594
  Purpose

We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 18 years. A consistent objective throughout this tudy is to obtain a comprehensive assessment of the natural history and progression of the multiple secondary features of osteogenesis imperfecta. In addition to radiographic, bone density, physical rehabilitation and dental manifestations, we will assess the neurological, cardiovascular, pulmonary, and audiological systems.

The major objectives of this protocol are the study of neurological features of OI, the rehabilitation and physical therapy studies, pulmonary function studies, and genetic and molecular biology aspects of OI. One major objective of these studies of secondary features is to determine the incidence of basilar invagination and develop a monitoring and management plan for this neurological feature. A second major objective in this study is to expand the intensive rehabilitation and physical therapy studies of children with types III and IV OI. This objective continues the work that has been done in the Rehabilitation Department of the Clinical Center for the past 20 years on these patients. However, the focus of this objective is changing to include studies of scoliosis and its effect on function, studies of chest proportions and rib deformities, studies of obesity in children with OI, and studies of nonkinetic variables related to motor performance, such as temperament, competence, coping, and resilience in children with OI. The third major objective is the longitudinal study of pulmonary function in children with types III and IV OI. It is well known that cardiopulmonary complications are a major cause of disability and death in adults with OI; the development of these complications, and whether susceptible individuals can be identified in childhood, is unknown. The final major objective in this study is the continued study of the genetic and molecular biology aspect of OI. Patients will have skin biopsies for collagen studies at the biochemical and molecular level. Parents will have blood drawn for determination of mosaic status for the mutation that causes their child's OI. These studies will provide further information on genotype/phenotype correlation and other variables in OI genetics. As appropriate, bone chips from emergency or elective surgical procedures on the participants will be used to study osteoblast function in OI.

...


Condition
Dwarfism
Osteogenesis Imperfecta

Genetics Home Reference related topics: Baller-Gerold syndrome Crouzon syndrome Melnick-Needles syndrome osteogenesis imperfecta pseudoachondroplasia
MedlinePlus related topics: Dwarfism Osteogenesis Imperfecta Rehabilitation
U.S. FDA Resources
Study Type: Observational
Official Title: Evaluation and Intervention for Ambulation, Basilar Invagination, and Secondary Effects of Osteogenesis Imperfecta

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 100
Study Start Date: January 1997
Detailed Description:

We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 25 years. A consistent objective throughout this study is to obtain a comprehensive assessment of the natural history and progression of the multiple secondary features of osteogenesis imperfecta. In addition to radiographic, bone density, physical rehabilitation and dental manifestations, we will assess the neurological, cardiovascular, pulmonary, and audiological systems.

The major objectives of this protocol are the study of neurological features of OI, the rehabilitation and physical therapy studies, pulmonary function studies, and genetic and molecular biology aspects of OI. One major objective of these studies of secondary features is to determine the incidence of basilar invagination and develop a monitoring and management plan for this neurological feature. A second major objective in this study is to expand the intensive rehabilitation and physical therapy studies of children with types III and IV OI. This objective continues the work that has been done in the Rehabilitation Department of the Clinical Center for the past 20 years on these patients. However, the focus of this objective is changing to include studies of scoliosis and its effect on function, studies of chest proportions and rib deformities, studies of obesity in children with OI, and studies of nonkinetic variables related to motor performance, such as temperament, competence, coping, and resilience in children with OI. The third major objective is the longitudinal study of pulmonary function in children with types III and IV OI. It is well known that cardiopulmonary complications are a major cause of disability and death in adults with OI; the development of these complications, and whether susceptible individuals can be identified in childhood, is unknown. The final major objective in this study is the continued study of the genetic and molecular biology aspect of OI. Patients will have skin biopsies for collagen studies at the biochemical and molecular level. Parents will have blood drawn for determination of mosaic status for the mutation that causes their child's OI. These studies will provide further information on genotype/phenotype correlation and other variables in OI genetics. As appropriate, bone chips from emergency or elective surgical procedures on the participants will be used to study osteoblast function in OI.

  Eligibility

Ages Eligible for Study:   up to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Children will be recruited from the United States. This recruitment will be accomplished by our contacts with the Osteogenesis Imperfecta Foundation, parent-to-parent communication, and outside referrals from other health care providers.

There are no exclusionary criteria related to race or gender for this protocol.

Children enrolled in this study will be limited to those with Sillence Types III and IV OI, as determined by clinical and genetic criteria.

Patients age birth to 10 years at enrollment will be considered for this protocol.

Children who have not had skin biopsy done for collagen analysis at another facility are preferred for participation in this study. However, previous skin biopsy at another facility will not preclude participation in this protocol.

EXCLUSION CRITERIA:

Children who can be expected to attain at least some degree of ambulatory skill or have high potential for achieving independent locomotion with assistive technology.

Children who are clinically too severe to benefit from this program are defined by the following criteria:

  1. the ratio of head circumference age (the age for which the child's head or body size falls at the 50th percentile) to body length age (the age for which the child's length falls at the 50th percentile) is 7:1 or greater;
  2. Children who are 24 months of age, and who are unable to sit unsupported for 60 seconds and are unable to demonstrate the ability to prop themselves on upper extremities in the prone position;
  3. children who have other significant medical problems, especially severe cardiopulmonary problems, which have an impact on their physical development.

Compliance with the visit schedule, maintenance of the physical therapy program, and completion of the measurement tools are central to our analysis of the outcomes of this study. Failure to comply with these conditions will constitute exclusion criteria.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001594

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 970064, 97-CH-0064
Study First Received: November 3, 1999
Last Updated: December 5, 2008
ClinicalTrials.gov Identifier: NCT00001594  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Osteogenesis Imperfecta
Basilar Invagination
Osteogenesis Imperfecta

Study placed in the following topic categories:
Dwarfism
Spinal Diseases
Osteogenesis Imperfecta
Osteogenesis imperfecta
Collagen Diseases
Craniofacial Abnormalities
Osteochondrodysplasias
Endocrine System Diseases
Bone Diseases
Musculoskeletal Abnormalities
Musculoskeletal Diseases
Genetic Diseases, Inborn
Neoplasm Metastasis
Platybasia
Bone Diseases, Developmental
Connective Tissue Diseases
Endocrinopathy
Congenital Abnormalities

ClinicalTrials.gov processed this record on January 15, 2009